Overview

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Status:
Unknown status

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

Phase I: evaluate the safety and tolerability two different dosing regimens of Thymosin alpha 1 in patients with advanced EGFR mutation positive NSCLC on Standard of Care (SoC) therapy. Phase II: evaluate the efficacy in terms of PFS of Thymosin alpha 1 in patients with advanced EGFR mutant NSCLC taking SoC as compared to SoC alone.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

SciClone Pharmaceuticals

Treatments:

Afatinib
Gefitinib
Thymalfasin